Interestingly, low activity polymorphisms in TPMT involved in the regulation of the thiopurine pathway and metabolism of 6-mercaptopurine, are risk factors for ALL and strongly influence drug efficacy and clinical toxicity [32,33,34]. This evidence concerns the gene TPMT and acute lymphoblastic leukemia.